Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Continuous Infusion of Dexamethasone Plus Tramadol Adjunct to Morphine PCA After Abdominal Hysterectomy (DTMPCA)
This study has been completed.
Sponsors and Collaborators: Nanjing Medical University
HRSA/Maternal and Child Health Bureau
Information provided by: Nanjing Medical University
ClinicalTrials.gov Identifier: NCT00564603
  Purpose

Dexamethasone has been recognized as an antiemetic agent after surgeries, and the combination of dexamethasone and tramadol remained stable in solution up to 5 days. In addition, i.v. basal infusion of tramadol is a certified technique in postoperative pain management. We purposed that combined administration of dexamethasone and tramadol adjunct to i.v. morphine is an effective way in treating postoperative pain.


Condition Intervention Phase
Postoperative Pain
Post Operative Analgesia
Patient-Controlled Analgesia
Abdominal Surgeries
Drug: Dexamethasone Sodium Phosphate Injection
Other: 0.9% Saline
Phase IV

MedlinePlus related topics: Hysterectomy
Drug Information available for: Dexamethasone Dexamethasone acetate Dexamethasone Sodium Phosphate Doxiproct plus Sodium chloride Tramadol hydrochloride Tramadol Sodium phosphate, dibasic
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy

Further study details as provided by Nanjing Medical University:

Primary Outcome Measures:
  • Visual analog scale (VAS) of pain [ Time Frame: 0-48h after surgeries ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • First requirement of morphine; Total morphine consumption; VAS sedation; VAS satisfaction; Side effects; Overall conditions of patients; [ Time Frame: 0-48h after surgeries ] [ Designated as safety issue: Yes ]

Enrollment: 300
Study Start Date: August 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Placebo Comparator
Saline with same volume added to tramadol infusion combined with morphine PCA.
Other: 0.9% Saline
Saline, in same volume of 2mL
2: Active Comparator
Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
Drug: Dexamethasone Sodium Phosphate Injection
Dexamethasone, 10mg, continuously infused up to 48h after surgeries.

  Eligibility

Ages Eligible for Study:   19 Years to 64 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ASA physical status I-II
  2. Chinese
  3. 19-64yr
  4. Uterus myoma

Exclusion Criteria:

  1. Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records.
  2. Participants younger than 18yr,older than 65yr or pregnancy was eliminated.
  3. Due to the significant changes in vital signs might affect cognition of pain and that of sensation, over 20% variation of these records from the baselines or below 92% of SpO2 under 20-40% nasal tube oxygen at any time should be excluded from the study.
  4. Those who were not willing to or could not finish the whole study at any time.
  5. Any patient who exhibited a combative or incoherent state of PCA analgesia would be excluded from the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00564603

Locations
China, Jiangsu
Nanjing Maternal and Child Care Hospital
Nanjing, Jiangsu, China, 210004
Sponsors and Collaborators
Nanjing Medical University
HRSA/Maternal and Child Health Bureau
Investigators
Study Director: XiaoFeng Shen, MD Nanjing Medical University
  More Information

Responsible Party: Nanjing Maternal and Child Health Hospital ( XiaoFeng Shen )
Study ID Numbers: NMU-2579-5FW, 06NMUZ028
Study First Received: November 26, 2007
Last Updated: April 17, 2008
ClinicalTrials.gov Identifier: NCT00564603  
Health Authority: China: Ministry of Health;   China: Nanjing Medical University

Keywords provided by Nanjing Medical University:
Glucocorticoid
Opioids
Balanced analgesia

Study placed in the following topic categories:
Dexamethasone
Morphine
Signs and Symptoms
Sodium phosphate
Postoperative Complications
Tramadol
Pain
Dexamethasone acetate
Pain, Postoperative

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Cathartics
Glucocorticoids
Hormones
Pharmacologic Actions
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009